Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT03827876
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Psoriasis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Last updated on ClinicalTrials.gov
- February 4, 2019
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Psoriasis Treatment Center of Central New Jersey · East Windsor, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.